Genelux Corporation (GNLX)
Last updated: 2026-10-21 10:25:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Genelux Corporation (GNLX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.49, with a market capitalization of $110.85M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.29 to $8.54. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$110.85M | |
$2.43 | |
$40.98 | |
$1.60 | |
$2.45 | |
327.47K | |
296.24K | |
-- | |
$8.54 | |
$2.29 | |
-- | |
-- |
Genelux Corporation (GNLX) Pre-Market Stock Price
Genelux Corporation (GNLX) is trading at $2.43 in pre-market trading as of 2026-10-20 23:31:00, down 0.82% ($0.02) from the previous close of $2.45
Pre-market trading shows how investors are pricing GNLX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Genelux Corporation (GNLX) 7-Day Stock Price Change
Over the past seven days, Genelux Corporation (GNLX) moved from $2.55 to $2.49, representing a decline of 2.04% ($0.05).
The stock traded between $2.32 and $2.61 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 314.67 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
GNLX 52-Week Price Position
Position in Range: 3.3%
GNLX is currently trading at $2.49, placing it 3.3% of the way from its 52-week low of $2.29 to its 52-week high of $8.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Genelux Corporation (GNLX)?
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Genelux Corporation Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 26 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Genelux Corporation (GNLX) Stock on MEXC
Eligible investors can buy real shares of Genelux Corporation (GNLX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Genelux Corporation (GNLX) stock price today?
2.Is GNLX stock going up or down today?
3.What is GNLX pre-market price?
4.What is GNLX after-hours price?
5.Is GNLX stock trading now?
6.Where does GNLX sit relative to its 52-week high and low?
7.What sector is Genelux Corporation in?
8.What is Genelux Corporation's market capitalization and where is it listed?
9.How is GNLX valued in terms of P/E ratio and EPS?
10.Does Genelux Corporation pay a dividend?
Explore More US Stocks
Search Stocks
GNLX Stock Calculator
Estimate the value between GNLX shares and USD.
GNLX Shares to USD
1.00 GNLX shares = 2.493 USD
Calculations are estimates based on the latest available price and are for reference only.



